AYTU BIOPHARMA, INC
AYTU evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AYTU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AYTU
Aytu BioPharma is a commercial-stage specialty pharmaceutical company focused on prescription products for central nervous system disorders, including major depressive disorder and ADHD, with a portfolio of branded and legacy pediatric medicines.
Key risk: Accumulated deficit and ongoing losses
BioSniper Score
Based on 5 of 6 signals
Market Cap
$24.1M
Cash Runway
27.9 moLead Asset
aciphex (Approved)Next Catalyst
Patent_Expiry · Mar 29, 2029Financial data as of Mar 31, 2026.
Tracking 7 pipeline candidates · 1 clinical trial · 6 catalysts · 3 FDA decisions for AYTU BIOPHARMA, INC.
Aytu BioPharma is a commercial-stage specialty pharmaceutical company focused on prescription products for central nervous system disorders, including major depressive disorder and ADHD, with a portfolio of branded and legacy pediatric medicines.
- Commercial-stage company with three product portfolios: EXXUA for MDD, an ADHD portfolio, and a Pediatric Portfolio of legacy products [sec_mda · as of 2026-02-03].
- Reported cash & equivalents of $26.7M, total revenue of $12.4M, net loss of -$5.6M, shareholders' equity of $19.0M, and total debt of $11.4M as of 2026-03-31 [sec].
- Accumulated deficit of $333.5M as of June 30, 2025, with a net loss of $13.6M for the fiscal year ended June 30, 2025 [sec_mda · as of 2025-09-23].
- Manufacturing for Adzenys and Cotempla products was transitioned to a U.S.-based contract manufacturer in 2024 to improve profitability [sec_mda · as of 2025-09-23].
- A $100.0M shelf registration statement (2024 Shelf) remains available for future capital raising as of the latest filing [sec_mda · as of 2025-11-13].
What works
- Revenue-generating commercial portfolio with three distinct product categories (EXXUA, ADHD, Pediatric) providing diversified cash flow streams [sec_mda · as of 2026-02-03].
- Manufacturing transition of Adzenys and Cotempla to a U.S.-based contract manufacturer in 2024 is expected to improve product profitability [sec_mda · as of 2025-09-23].
- International collaboration agreements for certain ADHD products may expand geographic reach and revenue potential [sec_mda · as of 2026-02-03].
What to weigh
- History of significant losses with an accumulated deficit of $333.5M as of June 30, 2025, and a net loss of $13.6M for fiscal 2025 [sec_mda · as of 2025-09-23].
- Total debt of $11.4M as of 2026-03-31 and ongoing payment obligations, including a $4.3M settlement liability to Tris and other milestone payments [sec_mda · as of 2025-05-14].
- Reliance on third-party contract manufacturers for all product production introduces supply chain and quality control risks [sec_mda · as of 2026-02-03].
From the filings
Quoted directly from source documents.
Company focuses on commercializing prescription pharmaceuticals across three portfolios
“Our business from continuing operations is focused on the commercialization of our prescription pharmaceutical products sold primarily through third party wholesalers, distributors and pharmacies and which primarily consists of three product portfolios.”
SEC MD&A · February 3, 2026
Significant accumulated deficit and net loss
“Our net loss was $13.6 million for the year ended June 30, 2025, and as of June 30, 2025, we had an accumulated deficit of $333.5 million.”
SEC MD&A · September 23, 2025
Manufacturing transition to improve profitability
“2024, we successfully completed the transition of all manufacturing of our Adzenys and Cotempla products to a United States-based third-party contract manufacturer to improve the profitability of these products.”
SEC MD&A · September 23, 2025
Remaining availability under shelf registration
“Through the filing date of this Annual Report, $100.0 million remains available under the 2024 Shelf.”
SEC MD&A · November 13, 2025
Catalyst timeline
- 2029-03-29 · Patent_Expiry · KARBINAL ER — Patent/exclusivity expiry for KARBINAL ER could open the product to generic competition.
- 2030-09-02 · Patent_Expiry · EXXUA — Patent/exclusivity expiry for EXXUA may affect its market exclusivity.
- 2032-06-28 · Patent_Expiry · ADZENYS XR-ODT — Patent/exclusivity expiry for ADZENYS XR-ODT could lead to generic entry.
- 2032-08-07 · Patent_Expiry · ZOLPIMIST — Patent/exclusivity expiry for ZOLPIMIST may impact its branded sales.
- 2033-05-29 · Patent_Expiry · BELSOMRA — Patent/exclusivity expiry for BELSOMRA could reduce revenue from this product.
- 2038-01-25 · Patent_Expiry · COTEMPLA XR-ODT — Patent/exclusivity expiry for COTEMPLA XR-ODT is a longer-term consideration.
Risks & what to watch (4)›
Key risks
- Accumulated deficit and ongoing losses — Accumulated deficit of $333.5M and net loss of $13.6M in fiscal 2025; profitability not yet achieved [sec_mda · as of 2025-09-23].
- Debt and milestone payment obligations — Total debt of $11.4M plus $4.3M settlement liability to Tris and other milestone payments due [sec_mda · as of 2025-05-14].
- Dependence on third-party manufacturers — All products manufactured by CMOs, creating supply chain and quality control risks [sec_mda · as of 2026-02-03].
- Patent expirations on key products — Patent/exclusivity expirations for KARBINAL ER (2029), EXXUA (2030), and other products could impact future revenue [catalyst].
What to watch
- Revenue growth trajectory and path to profitability, given ongoing net losses [sec_mda · as of 2025-09-23].
- Ability to manage debt and milestone payment obligations, including the Tris settlement [sec_mda · as of 2025-05-14].
- Commercial performance of EXXUA and ADHD portfolio, especially under international collaboration agreements [sec_mda · as of 2026-02-03].
- Potential capital raises under the $100M shelf registration and impact on shareholder dilution [sec_mda · as of 2025-11-13].
Sources: SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run AYTU BIOPHARMA, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AYTU BIOPHARMA, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
27.9 months
D/E 2.18 · 0% dilution
Lead: Approved
7 candidates
6 upcoming, next in ~942d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$7.9M
| Holder | Shares | Value |
|---|---|---|
| arete wealth advisors, llc | 49,549 | $4.0M |
| vanguard capital management llc | 522,292 | $1.4M |
| diadema partners lp | 353,077 | $964K |
| two sigma investments, lp | 121,973 | $333K |
| renaissance technologies llc | 93,723 | $256K |
| geode capital management, llc | 92,636 | $253K |
| vanguard fiduciary trust co | 47,048 | $128K |
| dimensional fund advisors lp | 43,585 | $119K |
| citadel advisors llc | 36,841 | $101K |
| bellevue asset management, llc | 25,013 | $68K |
Showing top 10 of 33 institutional holders of AYTU BIOPHARMA, INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 14.8
- Shares short
- 505,368
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AYTU short interestGovernance
Frequently asked questions
What is the AI investment thesis for AYTU BIOPHARMA, INC?
Aytu BioPharma is a commercial-stage specialty pharmaceutical company focused on prescription products for central nervous system disorders, including major depressive disorder and ADHD, with a portfolio of branded and legacy pediatric medicines.
What is AYTU BIOPHARMA, INC's lead drug candidate?
AYTU BIOPHARMA, INC's most advanced tracked candidate is aciphex (Approved).
What is AYTU BIOPHARMA, INC's next catalyst?
AYTU BIOPHARMA, INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: KARBINAL ER" — expected March 29, 2029.
Who is the CEO of AYTU BIOPHARMA, INC?
Mr. Joshua R. Disbrow is the chief executive officer of AYTU BIOPHARMA, INC (AYTU).
Where is AYTU BIOPHARMA, INC headquartered?
AYTU BIOPHARMA, INC (AYTU) is headquartered in Denver, CO, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.